Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs Siltuximab (Primary)
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Therapeutic Use
- 04 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 04 Nov 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
- 01 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.